In the News

For media inquiries, please contact Susan Bernat – 216.312.4369

01/08/2021

Breath-Based Diagnostics Gain Traction as Potential Method for Detecting SARS-CoV-2

As the COVID-19 pandemic has ravaged the globe and strained diagnostic resources, many players have entered or expanded their presence on the scene to interrogate new methods of testing for SARS-CoV-2. 
One of those methods is the use of breath samples for diagnosing the virus, and a variety of companies and research teams from around the world are developing tests that seek to detect SARS-CoV-2 in the breath, although no such test has received Emergency Use Authorization from the US Food and Drug Administration.   
 


12/30/2020

Top 10 Medical Innovations for 2021

COVID-19 has dominated headlines for months, but science continues to move medicine forward, beyond the pandemic. According to Cleveland Clinic’s annual ranking of medical innovations, expanded access to medications for cystic fibrosis and hepatitis c, take two of the top ten spots.


12/30/2020

5 Medical Innovations You Probably Didn’t Notice Happened in 2020

From breakthroughs in oncology, gene therapies, and heart health, to the development of COVID-19 vaccines that are now being administered domestically and around the world, there’s a lot that the medical community can be proud of in 2020.


12/29/2020

‘NeuroDesign’ Fellowship Aims to Shape Next Generation of Neurosurgery Entrepreneurs

Cleveland Clinic’s Neurological Institute has joined forces with Case Western Reserve University’s Case School of Engineering to inaugurate the Cleveland NeuroDesign Innovation Fellowship, designed to train neurosurgeons and biomedical engineers to be successful innovators.


12/21/2020

Anixa Biosciences and Cleveland Clinic Announce FDA Clearance to Initiate Clinical Trial of Breast Cancer Vaccine

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its breast cancer vaccine.

 


12/01/2020

Anixa Biosciences Announces Licensing Agreement with Cleveland Clinic for Ovarian Cancer Vaccine Technology

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that it has entered into a license agreement with Cleveland Clinic for exclusive, world-wide rights to an innovative ovarian cancer vaccine technology. 


11/10/2020

Cleveland Clinic Outlines Top 10 Medical In­no­va­tions for 2021

First up is gene therapy for hemoglobinopathies. Simply put, research for gene therapy for blood disorders will help people, such as those with sickle cell anemia, make hemoglobin molecules that'll function properly.


10/21/2020

Cleveland Clinic, BreathTech will work together to develop Covid-19 breath test

Cleveland Clinic has agreed to work with a Texas company to develop a non-invasive device that uses your breath to identify Covid-19.


10/21/2020

Cleveland Clinic's Top 10 Medical Innovations for 2021

The circumstances surrounding Cleveland Clinic's Medical Innovation Summit was certainly this year. The healthcare industry held a virtual event due to restrictions caused by the pandemic. However, COVID-19 did not stop Cleveland Clinic from displaying its Top 10 Innovations for 2021. Here is the list of breakthrough devices and therapies that are set to make an impact next year.


10/21/2020

Cleveland Clinic and Astrotech Subsidiary Partner to Develop a Rapid COVID-19 Breath Test

Astrotech Corporation’s (NASDAQ: ASTC) subsidiary, BreathTech Corporation announced today that it has signed a joint development agreement (JDA) with Cleveland Clinic to explore leveraging Astrotech’s BreathTest-1000™ mass spectrometer to rapidly screen for COVID-19 or related indicators. The goal of the agreement is to develop a non-invasive device that will use breath samples to identify COVID-19 strains, with the potential to provide a low-cost, self-service screening option that could be deployed on a large-scale.


   < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >   

Get In Touch With Us